Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C18H26NO3.NO3 |
| Molecular Weight | 366.4088 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[O-][N+]([O-])=O.C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C3=CC=CC=C3
InChI
InChIKey=NEDVJZNVOSNSHF-KUMOIWDRSA-N
InChI=1S/C18H26NO3.NO3/c1-19(2)14-8-9-15(19)11-16(10-14)22-18(21)17(12-20)13-6-4-3-5-7-13;2-1(3)4/h3-7,14-17,20H,8-12H2,1-2H3;/q+1;-1/t14-,15+,16+,17?;
Methylatropine (methylatroponium) is a belladonna derivative. In 1902 the Bayer Company introduced atropine methonitrate, a quaternary ammonium salt of atropine (Eumydrin), as a mydriatic for dilation of the pupil during ophthalmic examination. Due to its highly polar nature it penetrates less readily into the central nervous system than atropine and was therefore introduced for relieving pyloric spasms in infants. Atropine methyl nitrate is a muscarinic acetylcholine receptor antagonist that does not cross the blood-brain barrier. Atropine methyl nitrate has been used for its peripheral muscarinic effects (targeting the bladder, respiratory tract, and to block parasympathetic signaling to the heart, among others) and to separate central from peripheral nervous system effects, or to protect against peripheral side effects when using muscarinics that do cross the blood brain barrier.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19523969http://www.sigmaaldrich.com/catalog/product/sigma/sml0732?lang=es®ion=ES
Curator's Comment: Atropine methyl nitrate is a muscarinic acetylcholine receptor antagonist that does not cross the blood brain barrier.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18799813Helgolaender Wissenschaftliche Meeresuntersuchungen (1966), 14, (1-2), 583-90.
Curator's Comment: # Bayer
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
0.8 mg multiple, oral (total) |
unhealthy, 1 week n = 1 Health Status: unhealthy Age Group: 1 week Population Size: 1 Sources: |
Other AEs: Paralytic ileus, Hypotonic urinary bladder... Other AEs: Paralytic ileus (1 patient) Sources: Hypotonic urinary bladder (1 patient) |
0.4 mg 6 times / day multiple, oral Dose: 0.4 mg, 6 times / day Route: oral Route: multiple Dose: 0.4 mg, 6 times / day Sources: |
unhealthy, 2 month n = 1 Health Status: unhealthy Age Group: 2 month Sex: M Population Size: 1 Sources: |
Other AEs: Dilated pupils, Fever... |
2.5 mL 1 times / day multiple, oral Dose: 2.5 mL, 1 times / day Route: oral Route: multiple Dose: 2.5 mL, 1 times / day Sources: |
unhealthy, 37 days n = 1 Health Status: unhealthy Age Group: 37 days Sex: M Population Size: 1 Sources: |
Other AEs: Paralytic ileus... |
16 mg multiple, oral (total) Highest studied dose |
unhealthy, 7 weeks n = 1 Health Status: unhealthy Age Group: 7 weeks Population Size: 1 Sources: |
Other AEs: Irritable, Hypertonia... Other AEs: Irritable (1 patient) Sources: Hypertonia (1 patient) Dilated pupils (1 patient) |
0.1 mg 1 times / day multiple, oral (starting) Dose: 0.1 mg, 1 times / day Route: oral Route: multiple Dose: 0.1 mg, 1 times / day Sources: |
unhealthy, babies n = 15 Health Status: unhealthy Age Group: babies Population Size: 15 Sources: |
Disc. AE: Abdominal distension... AEs leading to discontinuation/dose reduction: Abdominal distension Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Hypotonic urinary bladder | 1 patient | 0.8 mg multiple, oral (total) |
unhealthy, 1 week n = 1 Health Status: unhealthy Age Group: 1 week Population Size: 1 Sources: |
| Paralytic ileus | 1 patient | 0.8 mg multiple, oral (total) |
unhealthy, 1 week n = 1 Health Status: unhealthy Age Group: 1 week Population Size: 1 Sources: |
| Dilated pupils | 0.4 mg 6 times / day multiple, oral Dose: 0.4 mg, 6 times / day Route: oral Route: multiple Dose: 0.4 mg, 6 times / day Sources: |
unhealthy, 2 month n = 1 Health Status: unhealthy Age Group: 2 month Sex: M Population Size: 1 Sources: |
|
| Fever | 0.4 mg 6 times / day multiple, oral Dose: 0.4 mg, 6 times / day Route: oral Route: multiple Dose: 0.4 mg, 6 times / day Sources: |
unhealthy, 2 month n = 1 Health Status: unhealthy Age Group: 2 month Sex: M Population Size: 1 Sources: |
|
| Paralytic ileus | grade 5 | 2.5 mL 1 times / day multiple, oral Dose: 2.5 mL, 1 times / day Route: oral Route: multiple Dose: 2.5 mL, 1 times / day Sources: |
unhealthy, 37 days n = 1 Health Status: unhealthy Age Group: 37 days Sex: M Population Size: 1 Sources: |
| Dilated pupils | 1 patient | 16 mg multiple, oral (total) Highest studied dose |
unhealthy, 7 weeks n = 1 Health Status: unhealthy Age Group: 7 weeks Population Size: 1 Sources: |
| Hypertonia | 1 patient | 16 mg multiple, oral (total) Highest studied dose |
unhealthy, 7 weeks n = 1 Health Status: unhealthy Age Group: 7 weeks Population Size: 1 Sources: |
| Irritable | 1 patient | 16 mg multiple, oral (total) Highest studied dose |
unhealthy, 7 weeks n = 1 Health Status: unhealthy Age Group: 7 weeks Population Size: 1 Sources: |
| Abdominal distension | Disc. AE | 0.1 mg 1 times / day multiple, oral (starting) Dose: 0.1 mg, 1 times / day Route: oral Route: multiple Dose: 0.1 mg, 1 times / day Sources: |
unhealthy, babies n = 15 Health Status: unhealthy Age Group: babies Population Size: 15 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effects of atropine sulfate, methylatropine nitrate (metropine) and homatropine hydrobromide on adult human eyes. | 1946 Sep |
|
| Clinical pertussis treated with methyl atropine nitrate (eumydrin). | 1950 Oct 7 |
|
| Ganglionic blocking action of atropine and methylatropine. | 1953 Dec |
|
| The difference in the effects of tertiary and quaternary ammonium bases (proserine, serine, methylatropine and atropine) depending on the method of administration. | 1962 Mar |
|
| Effect of thyrotropin-releasing hormone (TRH) on local cerebral glucose utilization, by the autoradiographic 2-deoxy[14C]glucose method, in conscious and pentobarbitalized rats. | 1980 Oct |
|
| Pharmacological, hemodynamic and autonomic nervous system mechanisms responsible for the blood pressure and heart rate lowering effects of pergolide in rats. | 1984 Mar |
|
| Apparent reduction in baroreflex sensitivity to adenosine in conscious dogs. | 1985 Sep |
|
| Investigation into the cardioregulatory properties of the alpha 1-adrenoceptor blocker indoramin. | 1986 Feb |
|
| Bupivacaine inhibits baroreflex control of heart rate in conscious rats. | 2000 Jan |
|
| Cardiovascular effects of hypocretin-1 in nucleus of the solitary tract. | 2003 Apr |
|
| Cardiac effects of hypocretin-1 in nucleus ambiguus. | 2003 Jun |
|
| Inhibition of [18F]FP-TZTP binding by loading doses of muscarinic agonists P-TZTP or FP-TZTP in vivo is not due to agonist-induced reduction in cerebral blood flow. | 2003 Nov |
|
| Modulation of heart rate variability during severe hemorrhage at different rates in conscious rats. | 2009 Oct 5 |
|
| Effect of ghrelin on glucose-insulin homeostasis: therapeutic implications. | 2010 |
|
| Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism. | 2010 Jun 25 |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: A drop of this solution placed on the surface of the tongue is rapidly absorbed and the treatment and absorption are not interfered with by the vomiting.
Pyloric stenosis: The first dose was usually 0.5-1 ml (0.05-0.1 mgm. per dose), increasing by 0.5 ml at each feed till a dose of 2-3 ml, six times daily, was reached, i.e. 1.2-1.8 mgm. in twenty-four hours.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB12156MIG
Created by
admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
|
PRIMARY | |||
|
436
Created by
admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
|
PRIMARY | |||
|
m2136
Created by
admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
|
PRIMARY | Merck Index | ||
|
C174866
Created by
admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
|
PRIMARY | |||
|
759122
Created by
admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
|
PRIMARY | |||
|
DTXSID0045543
Created by
admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
|
PRIMARY | |||
|
200-156-1
Created by
admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
|
PRIMARY | |||
|
100000079567
Created by
admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
|
PRIMARY | |||
|
C006649
Created by
admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
|
PRIMARY | |||
|
52-88-0
Created by
admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
|
PRIMARY | |||
|
Q48D9J47K2
Created by
admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
|
PRIMARY | |||
|
CHEMBL1187724
Created by
admin on Fri Dec 15 15:10:35 GMT 2023 , Edited by admin on Fri Dec 15 15:10:35 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
